璇戝悕瀵圭収琛細

浣庡瘑搴﹁剛铔嬬櫧锛圠DL, low density lipoprotein锛?/p>

楂樺瘑搴﹁剛铔嬬櫧锛圚DL, high density lipoprotein锛?/p>

浠栨眬锛圫tatin锛?/p>

绔嬫櫘濡ワ紙Lipitor锛岄€氱敤鍚岮torvastatin锛?/p>

渚濇姌楹﹀竷锛圗zetimibe锛?/p>

鑳嗘眮閰歌灟鍚堝墏锛圔ile acid sequestrants锛?/p>

鍒楀噣锛圠iflozin锛?/p>

绯栧熀鍖栧垎瀛愶紙GalNac锛?/p>

婧堕叾浣擄紙lysosome锛?/p>

瀹舵棌鎬ч珮鑳嗗浐閱囪鐥囷紙Familial hypercholesterolemia锛?/p>

缇庝紣浠栨眬锛圡evastatin锛?/p>

杩滆棨绔狅紙Akira Endo锛?/p>

绗竴涓夊叡锛圖aiichi Sankyo锛?/p>

浣庡瘑搴﹁剛铔嬬櫧鍙椾綋锛圠DL receptor锛?/p>

娲涗紣浠栨眬锛圠ovastatin锛?/p>

聽鍙傝€冩枃鐚細锛堜笂涓嬫粦鍔ㄥ彲娴忚锛?/p>

[1] Penn Medicine. (2018, Aug 02).聽Statins: What You Should Know.

https://www.pennmedicine.org/updates/blogs/heart-and-vascular-blog/2018/april/statins-what-you-should-know

[2] Harvard Health Publishing. (2017, Feb 06).聽How it鈥檚 made: Cholesterol production in your body.

https://www.health.harvard.edu/heart-health/how-its-made-cholesterol-production-in-your-body

[3] Luo, J., Yang, H., & Song, B.-L. (2020). Mechanisms and regulation of聽cholesterol homeostasis.聽Nature Reviews. Molecular Cell Biology,聽21(4), 225鈥?45.

[4] Lopaschuk, G. D., & Verma, S. (2020). Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors.聽JACC. Basic to Translational Science,聽5(6), 632鈥?44.

[5] Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020). Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.聽Molecular Therapy,聽28(8), 1759鈥?771.

[6] Nioi, P., Sigurdsson, A., Thorleifsson, G., Helgason, H., Agustsdottir, A. B., Norddahl, G. L., Helgadottir, A., Magnusdottir, A., Jonasdottir, A., Gretarsdottir, S., Jonsdottir, I., Steinthorsdottir, V., Rafnar, T., Swinkels, D. W., Galesloot, T. E., Grarup, N., J酶rgensen, T., Vestergaard, H., Hansen, T., 鈥?Krarup, N. T. (2016). Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease.聽The New England Journal of Medicine,聽374(22), 2131鈥?141.

[7] Wang, J.-Q., Li, L.-L., Hu, A., Deng, G., Wei, J., Li, Y.-F., Liu, Y.-B., Lu, X.-Y., Qiu, Z.-P., Shi, X.-J., Zhao, X., Luo, J., & Song, B.-L. (2022). Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion.聽Nature (London),聽608(7922), 413鈥?20.

[8] Endo A. (2010). A historical perspective on the discovery of statins.聽Proceedings of the Japan Academy. Series B, Physical and biological sciences,聽86(5), 484鈥?93.

[9] Nair, P. (2013). Brown and Goldstein: The Cholesterol Chronicles.聽Proceedings of the National Academy of Sciences - PNAS,聽110(37), 14829鈥?4832.

[10] Yamamoto, T., Davis, C. G., Brown, M. S., Schneider, W. J., Casey, M. L., Goldstein, J. L., & Russell, D. W. (1984). The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA.聽Cell,聽39(1), 27鈥?8.

[11] Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I., & Endo, A. (1978). Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase.聽The Journal of biological chemistry,聽253(4), 1121鈥?128.

[12] Abifadel, M., Varret, M., Rab猫s, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derr茅, A., Vill茅ger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., 鈥?Boileau, C. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.聽Nature genetics,聽34(2), 154鈥?56.

[13] Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005). Low LDL cholesterol in inpiduals of African descent resulting from frequent nonsense mutations in PCSK9.聽Nature genetics,聽37(2), 161鈥?65.

鍒剁増缂栬緫聽|聽灏忓湱鏈?/p>